Under the deal, Europroteome will use its proteomics and bioinformatics technologies to analyze serum samples from women with breast cancer. The resultant data will be aligned with a panel of cancer markers from Abbott. Combinations of markers will be selected for further development and integration into Abbott's instrument platforms, the companies said.
Abbott will pay Europroteome an upfront fee, as well as milestone payments. Abbott will also have an option for a royalty-bearing license to the results from the research collaboration, and well be responsible for commercial assay development and marketing.